Skandinaviska Enskilda Banken (SEB)’s Albany Molecular Research Inc AMRI Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-21,500	Closed	-$467K	–	759
2017 Q2	$467K	Sell	21,500 -82,100	-79%	-$1.49M	﹤0.01%	662
2017 Q1	$1.45M	Buy	+103,600	New	+$1.7M	0.01%	513
2016 Q4	–	Sell	-309,300	Closed	-$5.11M	–	769
2016 Q3	$5.11M	Buy	309,300 +16,200	+6%	+$240K	0.06%	255
2016 Q2	$3.94M	Hold	293,100	–	–	0.04%	295
2016 Q1	$4.48M	Buy	+293,100	New	+$4.59M	0.05%	260

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s AMRI Position: Q3 2017 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 21,500 shares — an estimated $467K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in AMRI in Q1 2016 and held it in 5 quarters. The position peaked at $5.11M in Q3 2016. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Skandinaviska Enskilda Banken (SEB) reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 21,500 Albany Molecular Research Inc shares in Q3 2017, an estimated $467K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 5 quarters.
Skandinaviska Enskilda Banken (SEB)'s Albany Molecular Research Inc position peaked at $5.11M in Q3 2016.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2017, filed 13 Nov 2017.